Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

C-Section pain relief: does ketorolac raise bleeding risk?

NCT ID NCT03805607

Knowledge-focused Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how ketorolac, a non-steroidal anti-inflammatory drug (NSAID) used for pain after cesarean delivery, affects platelet function and blood clotting. Researchers measured clotting in 40 women undergoing scheduled C-sections using special blood tests. The goal was to better understand bleeding risks when using this common painkiller after childbirth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Jan 2021

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant * Undergoing routine, scheduled cesarean section * Gestation \>37 weeks * Singleton gestation * Intraoperative anesthesia - 1.5 ml of intrathecal bupivicaine 0.75%, 25mcg of intrathecal fentanyl and 250 mcg of intrathecal morphine via Spinal or Combined Spinal Epidural Exclusion Criteria: * Pre-eclampsia with severe features or HELLP * Allergy to NSAIDs * Pre-existing bleeding disorder * Other major risk factor for postpartum hemorrhage (placenta accreta, large uterine fibroid) * Chronic kidney disease * Plt count less than 100k * Gastric ulcer or gastric bleeding * Pre-existing uterine bleeding or disseminated intravascular coagulation * Patient or Obstetrician refusal * Intraoperative exclusion criteria - Postpartum hemorrhage (EBL \>1000 ml) or unplanned intraoperative extension of surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Analgesia, obstetrical are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia blood coagulation disease Blood Loss, Surgical Pain Pain, Postoperative Postoperative Hemorrhage Postpartum Hemorrhage vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Analgesia, obstetrical Blood loss, postoperative Coagulation defect; postpartum Ketorolac adverse reaction Nonsteroidals (nsaids)toxicity Postoperative pain Postpartum hemorrhage

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.